Literature DB >> 22972827

Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.

Chivonne Moodley1, Mignon du Plessis, Kedibone Ndlangisa, Linda de Gouveia, Keith P Klugman, Anne von Gottberg.   

Abstract

From August 1999 through July 2002, hyperinvasive Neisseria meningitidis serogroup B (MenB) clonal complexes (CCs), namely, ST-32/ET-5 (CC32) and ST-41/44/lineage 3 (CC41/44), were predominant in the Western Cape Province of South Africa. This study analyzed MenB invasive isolates from a national laboratory-based surveillance system that were collected from January 2002 through December 2006. Isolates were characterized by pulsed-field gel electrophoresis (PFGE) (n = 302), and multilocus sequence typing (MLST) and PorA and FetA typing were performed on randomly selected isolates (34/302, 11%). In total, 2,400 cases were reported, with the highest numbers from Gauteng Province (1,307/2,400, 54%) and Western Cape Province (393/2,400, 16%); 67% (1,617/2,400) had viable isolates and 19% (307/1,617) were identified as serogroup B. MenB incidence remained stable over time (P = 0.77) (average incidence, 0.13/100,000 population [range, 0.10 to 0.16/100,000 population]). PFGE (302/307, 98%) divided isolates (206/302, 68%) into 13 clusters and 96 outliers. The largest cluster, B1, accounted for 25% of isolates (76/302) over the study period; its prevalence decreased from 43% (20/47) in 2002 to 13% (8/62) in 2006 (P < 0.001), and it was common in the Western Cape (58/76, 76%). Clusters B2 and B3 accounted for 10% (31/302) and 6% (19/302), respectively, and showed no significant change over time and were predominant in Gauteng. Randomly selected isolates from clusters B1, B2, and B3 belonged to CC32, CC41/44, and the new CC4240/6688, respectively. Overall, 15 PorA and 12 FetA types were identified. MenB isolates were mostly diverse with no single dominant clone; however, CC32 and CC41/44 accounted for 35% and the new CC4240/6688 was the third most prevalent clone.

Entities:  

Mesh:

Year:  2012        PMID: 22972827      PMCID: PMC3486271          DOI: 10.1128/JCM.01079-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  65 in total

1.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

2.  PorA variable antigenic regions VR1, VR2, and VR3 of Neisseria meningitidis serogroups B and C isolated in Brazil from 1999 to 2004.

Authors:  Ivano de Filippis; Claudia Ferreira de Andrade; Luciete Silva; D Rebecca Prevots; Ana Carolina P Vicente
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

3.  Deletion of fetA gene sequences in serogroup B and C Neisseria meningitidis isolates.

Authors:  Jane W Marsh; Mary M O'Leary; Kathleen A Shutt; Lee H Harrison
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

4.  Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Authors:  Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

5.  Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Authors:  Jamie Findlow; Stephen Taylor; Audun Aase; Rachel Horton; Robert Heyderman; Jo Southern; Nick Andrews; Rita Barchha; Ewan Harrison; Ann Lowe; Emma Boxer; Charlotte Heaton; Paul Balmer; Ed Kaczmarski; Philipp Oster; Andrew Gorringe; Ray Borrow; Elizabeth Miller
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

Review 6.  Multilocus sequence typing for global surveillance of meningococcal disease.

Authors:  Carina Brehony; Keith A Jolley; Martin C J Maiden
Journal:  FEMS Microbiol Rev       Date:  2006-12-01       Impact factor: 16.408

Review 7.  A surveillance network for meningococcal disease in Europe.

Authors:  Caroline L Trotter; Manosree Chandra; Rosa Cano; Amparo Larrauri; Mary E Ramsay; Carina Brehony; Keith A Jolley; Martin C J Maiden; Sigrid Heuberger; Matthias Frosch
Journal:  FEMS Microbiol Rev       Date:  2006-12-01       Impact factor: 16.408

8.  Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.

Authors:  H Nøkleby; P Aavitsland; J O'Hallahan; B Feiring; S Tilman; P Oster
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

9.  Meningococcal disease in South Africa, 1999-2002.

Authors:  Garry B Coulson; Anne von Gottberg; Mignon du Plessis; Anthony M Smith; Linda de Gouveia; Keith P Klugman
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

10.  Spatiotemporal analysis of invasive meningococcal disease, Germany.

Authors:  Johannes Elias; Dag Harmsen; Heike Claus; Wiebke Hellenbrand; Matthias Frosch; Ulrich Vogel
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

View more
  1 in total

1.  Genetic diversity of Neisseria meningitidis serogroup C ST-4821 in China based on multiple-locus variable number tandem repeat analysis.

Authors:  Xiaoying Shan; Ji Zhang; Haijian Zhou; Bingqing Zhu; Li Xu; Zhujun Shao; Baofa Jiang
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.